Annual Revenue Threshold

No definition available.

Name:	abus_AnnualRevenueThreshold
Namespace Prefix:	abus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Gross Proceeds From Royalty Interest Sold

+ References

No definition available.

+ Details

Name:	abus_GrossProceedsFromRoyaltyInterestSold
Namespace Prefix:	abus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Non Cash Royalty Revenue Related To Sale Of Future Royalties

+ References

No definition available.

+ Details

Name:	abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
Namespace Prefix:	abus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percent of Costs related to Collaboration

+ References

No definition available.

+ Details

Name:	abus_PercentOfCostsRelatedToCollaboration
Namespace Prefix:	abus_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the potential milestone payments amount.

+ References

No definition available.

+ Details

Name:	abus_PotentialMilestonePayments
Namespace Prefix:	abus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Premium on Closing Stock Price

+ References

No definition available.

+ Details

Name:	abus_PremiumonClosingStockPrice
Namespace Prefix:	abus_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty Entitlements

+ References

No definition available.

+ Details

Name:	abus_RoyaltyEntitlements
Namespace Prefix:	abus_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the royalty guarantees commitments percentage.

+ References

No definition available.

+ Details

Name:	abus_RoyaltyGuaranteesCommitmentsPercentage
Namespace Prefix:	abus_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty interest, % interest

+ References

No definition available.

+ Details

Name:	abus_RoyaltyInterestPercentInterest
Namespace Prefix:	abus_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Interest Sold, Maximum Royalties For Buyer

+ References

No definition available.

+ Details

Name:	abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer
Namespace Prefix:	abus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the royalty payable.

+ References

No definition available.

+ Details

Name:	abus_RoyaltyPayable
Namespace Prefix:	abus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of revenue recognized previously reported as deferred income not accounted for under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

+ Details

Name:	us-gaap_DeferredIncomeRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 23
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-23

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-2

+ Details

Name:	us-gaap_IncomeTaxesPaid
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of revenue earned, classified as other, excluding interest income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_NoninterestIncomeOtherOperatingIncome
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of amortization of other deferred costs recognized in the income statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OtherAmortizationOfDeferredCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(7)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

+ Details

Name:	us-gaap_OtherCostAndExpenseOperating
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	srt_MajorCustomersAxis=abus_QiluPharmaceuticalCoLTDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=abus_QiluPharmaceuticalCoLTDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abus_BarinthusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abus_OMERSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abus_ArbutusBiopharmaCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abus_QiluPharmaceuticalCoLTDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abus_OneTimeUpfrontCashPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abus_ONPATTROGlobalNetSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abus_BarinthusBiotherapeuticsPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborations, contracts and licensing agreements (Details) $ / shares in Units, $ in Thousands					3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended	72 Months Ended
	Jan. 06, 2022 USD ($)	Jan. 05, 2022 USD ($)	Jul. 02, 2019 USD ($)	Jan. 01, 2019 USD ($)	Jun. 30, 2026 USD ($) product shares	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) product shares	Jun. 30, 2025 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2025 USD ($) shares	Jun. 30, 2025 USD ($)	Dec. 13, 2021 USD ($) $ / shares shares
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common shares, shares issued (in shares) \| shares					197,634,118		197,634,118			192,531,225
Number of royalty entitlements \| product					2		2
Non Cash Royalty Revenue Related To Sale Of Future Royalties							$ 361	$ 974
Qilu Pharmaceutical Co, LTD.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Income taxes paid										$ 4,400
Common Shares \| Qilu Pharmaceutical Co, LTD.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners												2.50%
Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest, % interest							0.75%
Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest, % interest							1.125%
Vaccitech
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Costs related to collaboration					$ 100	$ 300		600
Noninterest Income, Other Operating Income							$ (200)
OMERS
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Gross proceeds from sale of royalty interest. before advisory fees				$ 20,000
Entitlement of royalties to be received			$ 30,000	30,000
Future royalty payments			$ 30,000	$ 30,000
Non Cash Royalty Revenue Related To Sale Of Future Royalties							400	$ 1,000			$ 26,900
OMERS \| Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest, % interest			1.00%						1.00%
OMERS \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest, % interest			2.33%						2.33%
Arbutus Biopharma Corp
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty guarantees commitments percentage			100.00%	100.00%
Qilu Pharmaceutical Co, LTD.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential milestone payments												$ 245,000
Amortization of other deferred charges					100		200
Qilu Pharmaceutical Co, LTD. \| Common Shares
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common shares, shares issued (in shares) \| shares												3,579,952
Share price (in USD per share) \| $ / shares												$ 4.19
Premium on closing stock price (as a percent)												15.00%
Issuance of common shares pursuant to the Open Market Sale Agreement	$ 15,000
Qilu Pharmaceutical Co, LTD. \| One-Time Upfront Cash Payment
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from collaborators		$ 40,000
Qilu Pharmaceutical Co, LTD. \| Revenue from collaborations and licenses
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Deferred revenue recognized					$ 9,600
Qilu Pharmaceutical Co, LTD. \| Labor hours
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Deferred revenue recognized							500
ONPATTRO
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest sold, annual revenue threshold of highest tier			$ 500,000				$ 500,000		$ 500,000
Barinthus Biotherapeutics plc
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percent of Costs related to Collaboration					50.00%